<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115630</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0329</org_study_id>
    <nct_id>NCT05115630</nct_id>
  </id_info>
  <brief_title>Off-the-shelf NK Cells + SCT for Myeloid Malignancies</brief_title>
  <official_title>A Phase I/II Clinical Trial of &quot;Off-the-shelf&quot; NK Cell Administration in Combination With Allogeneic SCT to Decrease Disease Relapse in Patients With High-risk Myeloid Malignancies Undergoing Matched Related, Matched Unrelated, One Antigen Mismatched Unrelated, or Haploidentical Stem-cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn about the safety and effectiveness of&#xD;
      giving KDS-1001 in combination with a standard stem cell transplant to patients with acute&#xD;
      myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML).&#xD;
      KDS-1001 is a study product created using certain immune cells called natural killer (NK)&#xD;
      cells collected from a third-party donor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective&#xD;
&#xD;
      Assess the safety and effectiveness of &quot;off the shelf&quot; third party NK cells in combination&#xD;
      with allogeneic SCT in patients with myeloid malignancies.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      To assess NK cell related toxicities To estimate the proportion of patients with&#xD;
      engraftment/graft failure. To assess the rate of leukemia relapse, disease-free survival&#xD;
      (DFS), overall survival (OS), and GVHD-free, Relapse-free survival (GRFS) after&#xD;
      transplantation by one year.&#xD;
&#xD;
      To estimate the non-relapse mortality (NRM) at day 100, day 180 and 1 year post-transplant.&#xD;
&#xD;
      To estimate the cumulative incidence of grade 2-4 and grades 3-4 aGVHD at day 100. To assess&#xD;
      the rate of chronic GVHD within the first-year post transplantation. To assess rate of BK,&#xD;
      CMV, and Adenovirus infections. To assess MRD. To assess immune reconstitution&#xD;
      post-transplant&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Event Failure</measure>
    <time_frame>100 days post-transplant</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Myeloid Malignancies</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Days 3 and 4, you will receive cyclophosphamide by vein over about 3 hours to help lower the risk of graft-versus-host disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesna</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Days 3 and 4, You will also receive mesna by vein over 30 minutes every 4 hours for a total of 10 mesna doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgrastim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting on Day 7, you will begin to receive filgrastim as an injection under the skin 1 time a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day -7, you will receive melphalan by vein over about 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludarabine phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Days -7, -6, -5, and -4, you will receive fludarabine by vein about 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting on Day 5, you will begin receiving tacrolimus to help lower the risk of GVHD. You will begin by receiving it nonstop by vein until you are able to take it by mouth. You will then take tacrolimus by mouth 2 times a day for about 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>by mouth 3 times a day for 90 days or longer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total Body Irradiation One Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>on Day -2, you may receive 1 dose of total body irradiation (TBI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Mesna</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Filgrastim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine phosphate</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Fludarabine phosphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Mycophenolate mofetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Total Body Irradiation One Dose</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Total Body Irradiation One Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ages 18 to 65 years old at the time of enrollment.&#xD;
&#xD;
          -  Patients weighing at least 42 kg&#xD;
&#xD;
          -  Patient with the hematologic malignancies described below, as well as an HLA matched&#xD;
             related donor, HLA matched unrelated donor, a haploidentical related donor, or a one&#xD;
             antigen mismatched unrelated donor. HLA matching includes HLA A, B, C, and DR-B1.&#xD;
&#xD;
          -  Patients must have one of the following diseases:&#xD;
&#xD;
        Acute myeloid leukemia (AML):&#xD;
&#xD;
        a. First complete remission with high-risk features defined as: (i) Greater than 1 cycle of&#xD;
        induction therapy required to achieve remission; (ii) Preceding myelodysplastic syndrome&#xD;
        (MDS); Presence of FLT3 mutations or internal tandem duplication or other mutations&#xD;
        designated as adverse-risk by the ELN criteria&#xD;
&#xD;
        Adverse:&#xD;
&#xD;
          -  t(6;9)(p23;q34.1); DEK-NUP214&#xD;
&#xD;
          -  t(v;11q23.3); KMT2A rearranged&#xD;
&#xD;
          -  t(9;22)(q34.1;q11.2); BCR-ABL1&#xD;
&#xD;
          -  inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)&#xD;
&#xD;
          -  -5 or del(5q); -7; -17/abn(17p)&#xD;
&#xD;
          -  Complex karyotype, monosomal karyotype&#xD;
&#xD;
          -  Wild-type NPM1 and FLT3-ITDhigh&#xD;
&#xD;
          -  Mutated RUNX1&#xD;
&#xD;
          -  Mutated ASXL1&#xD;
&#xD;
          -  Mutated TP53 (iv) FAB M6 or M7 classification; (v) Adverse cytogenetics: -5, del 5q,&#xD;
             -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 or complex karyotype&#xD;
             [&gt; 3 abnormalities]; or other mutations designated as adverse-risk by the ELN&#xD;
             criteria; (vi) Treatment-related AML (vii) Primary induction failure with partial&#xD;
             response to therapy who achieve adequate cytoreduction, or (viii) Aplastic/hypoplastic&#xD;
             marrow with or without detectable persistent disease after induction chemotherapy or&#xD;
             after salvage chemotherapy.&#xD;
&#xD;
             b. Patients must be in (i) CR: complete remission, (ii) CRi: CR with incomplete&#xD;
             hematologic recovery, or (iii) MLFS: morphological leukemia-free state with less than&#xD;
             5% bone marrow blasts.&#xD;
&#xD;
        Patients cannot be beyond CR3, i.e., have relapsed more than 2 times.&#xD;
&#xD;
        Myelodysplastic syndromes (MDS):&#xD;
&#xD;
        a. De novo MDS with intermediate or high-risk IPSS scores. Patients with intermediate-1&#xD;
        features should have failed to respond to hypomethylating agent therapy, or patients with&#xD;
        treatment-related MDS.&#xD;
&#xD;
        Patients must have less than 10% bone marrow blasts&#xD;
&#xD;
        Chronic myeloid leukemia (CML):&#xD;
&#xD;
          1. Failed to achieve cytogenetic remission or have cytogenetic relapse after treatment&#xD;
             with at least 2 tyrosine kinase inhibitors, or&#xD;
&#xD;
          2. Accelerated phase or blast phase at any time.&#xD;
&#xD;
          3. Intolerant of available TKIs&#xD;
&#xD;
               -  Performance score of at least 70% by Karnofsky or 0 to 1 by ECOG.&#xD;
&#xD;
        Adequate major non-hematopoietic organ system function as demonstrated by:&#xD;
&#xD;
          1. Serum creatinine clearance equal or more than 50 ml/min (calculated with&#xD;
             Cockroft-Gault formula).&#xD;
&#xD;
          2. Bilirubin equal or less than 1.5 mg/dl except for Gilbert's disease. ALT or AST equal&#xD;
             or less than 200 IU/ml for adults. Conjugated (direct) bilirubin less than 2x upper&#xD;
             limit of normal.&#xD;
&#xD;
          3. Left ventricular ejection fraction equal or greater than 45%.&#xD;
&#xD;
          4. Diffusing capacity for carbon monoxide (DLCO) equal or greater than 60% predicted&#xD;
             corrected for hemoglobin.&#xD;
&#xD;
               -  Ability to understand and willingness to sign the written informed consent&#xD;
                  document.&#xD;
&#xD;
               -  Sexually active males and females of childbearing potential must agree to use a&#xD;
                  form of contraception considered effective and medically acceptable by the&#xD;
                  Investigator while on study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV positive; active hepatitis B or C.&#xD;
&#xD;
          -  Uncontrolled infections; PI is the final arbiter of this criterion.&#xD;
&#xD;
          -  Liver cirrhosis.&#xD;
&#xD;
          -  CNS involvement within 3 months prior to the transplant.&#xD;
&#xD;
          -  Positive pregnancy test in a woman with child bearing potential defined&#xD;
&#xD;
          -  as not post-menopausal for 12 months or no previous surgical sterilization.&#xD;
&#xD;
          -  Inability to comply with medical therapy or follow-up.&#xD;
&#xD;
          -  Patient with a known history of allergic reactions to any constituents of the product,&#xD;
             including a known history of allergic reactions to cellular products or DMSO.&#xD;
&#xD;
          -  Prior allogeneic SCT&#xD;
&#xD;
          -  Other malignancy/cancer diagnosis &lt;2 years ago, not including nonmelanoma skin cancer&#xD;
&#xD;
          -  Requiring systemic corticosteroids with prednisone dose &gt;10 mg or equivalent.&#xD;
&#xD;
          -  KDS-1001 Donor specific antibodies (dsa) &gt;5000 MFI units&#xD;
&#xD;
          -  KDS-1001 Donor anti-C1q positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Ramdial, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremy Ramdial, MD</last_name>
    <phone>(713) 745-0146</phone>
    <email>jlramdial@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Caner Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeremy Ramdial, MD</last_name>
      <phone>713-745-0146</phone>
      <email>jlramdial@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

